寨卡病毒疫苗和疗法的进展：系统综述

IF 1.9 4区医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Asian Pacific journal of tropical medicine Pub Date : 2024-03-01 DOI:10.4103/apjtm.apjtm_680_23

Shiza Malik, Khalid Muhammad, Omar Ahsan, Muhammad Tahir Khan, Ranjit Sah, Yasir Waheed

{"title":"寨卡病毒疫苗和疗法的进展：系统综述","authors":"Shiza Malik, Khalid Muhammad, Omar Ahsan, Muhammad Tahir Khan, Ranjit Sah, Yasir Waheed","doi":"10.4103/apjtm.apjtm_680_23","DOIUrl":null,"url":null,"abstract":"Zika virus (ZIKV) is the causative agent of a viral infection that causes neurological complications in newborns and adults worldwide. Its wide transmission route and alarming spread rates are of great concern to the scientific community. Numerous trials have been conducted to develop treatment options for ZIKV infection. This review highlights the latest developments in the fields of vaccinology and pharmaceuticals developments for ZIKV infection. A systematic and comprehensive approach was used to gather relevant and up-to-date data so that inferences could be made about the gaps in therapeutic development. The results indicate that several therapeutic interventions are being tested against ZIKV infection, such as DNA vaccines, subunit vaccines, live-attenuated vaccines, virus-vector-based vaccines, inactivated vaccines, virus-like particles, and mRNA-based vaccines. In addition, approved anti-ZIKV drugs that can reduce the global burden are discussed. Although many vaccine candidates for ZIKV are at different stages of development, none of them have received Food and Drug Authority approval for use up to now. The issue of side effects associated with these drugs in vulnerable newborns and pregnant women is a major obstacle in the therapeutic pathway.","PeriodicalId":8559,"journal":{"name":"Asian Pacific journal of tropical medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in Zika virus vaccines and therapeutics: A systematic review\",\"authors\":\"Shiza Malik, Khalid Muhammad, Omar Ahsan, Muhammad Tahir Khan, Ranjit Sah, Yasir Waheed\",\"doi\":\"10.4103/apjtm.apjtm_680_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Zika virus (ZIKV) is the causative agent of a viral infection that causes neurological complications in newborns and adults worldwide. Its wide transmission route and alarming spread rates are of great concern to the scientific community. Numerous trials have been conducted to develop treatment options for ZIKV infection. This review highlights the latest developments in the fields of vaccinology and pharmaceuticals developments for ZIKV infection. A systematic and comprehensive approach was used to gather relevant and up-to-date data so that inferences could be made about the gaps in therapeutic development. The results indicate that several therapeutic interventions are being tested against ZIKV infection, such as DNA vaccines, subunit vaccines, live-attenuated vaccines, virus-vector-based vaccines, inactivated vaccines, virus-like particles, and mRNA-based vaccines. In addition, approved anti-ZIKV drugs that can reduce the global burden are discussed. Although many vaccine candidates for ZIKV are at different stages of development, none of them have received Food and Drug Authority approval for use up to now. The issue of side effects associated with these drugs in vulnerable newborns and pregnant women is a major obstacle in the therapeutic pathway.\",\"PeriodicalId\":8559,\"journal\":{\"name\":\"Asian Pacific journal of tropical medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Pacific journal of tropical medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/apjtm.apjtm_680_23\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific journal of tropical medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/apjtm.apjtm_680_23","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

摘要

寨卡病毒（ZIKV）是一种病毒感染的病原体，可导致全球新生儿和成人出现神经系统并发症。其广泛的传播途径和惊人的传播速度引起了科学界的极大关注。为了开发治疗 ZIKV 感染的方案，已经进行了大量试验。本综述重点介绍了针对 ZIKV 感染的疫苗和药物研发领域的最新进展。我们采用了一种系统而全面的方法来收集相关的最新数据，以便对治疗开发方面的差距做出推断。研究结果表明，目前正在测试几种针对 ZIKV 感染的治疗干预措施，如 DNA 疫苗、亚单位疫苗、减毒活疫苗、病毒载体疫苗、灭活疫苗、病毒样颗粒和基于 mRNA 的疫苗。此外，还讨论了可减轻全球负担的已获批准的抗 ZIKV 药物。尽管许多 ZIKV 候选疫苗正处于不同的开发阶段，但迄今为止还没有一种疫苗获得食品药品管理局的批准。这些药物对易感新生儿和孕妇的副作用问题是治疗道路上的一大障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Advances in Zika virus vaccines and therapeutics: A systematic review

Zika virus (ZIKV) is the causative agent of a viral infection that causes neurological complications in newborns and adults worldwide. Its wide transmission route and alarming spread rates are of great concern to the scientific community. Numerous trials have been conducted to develop treatment options for ZIKV infection. This review highlights the latest developments in the fields of vaccinology and pharmaceuticals developments for ZIKV infection. A systematic and comprehensive approach was used to gather relevant and up-to-date data so that inferences could be made about the gaps in therapeutic development. The results indicate that several therapeutic interventions are being tested against ZIKV infection, such as DNA vaccines, subunit vaccines, live-attenuated vaccines, virus-vector-based vaccines, inactivated vaccines, virus-like particles, and mRNA-based vaccines. In addition, approved anti-ZIKV drugs that can reduce the global burden are discussed. Although many vaccine candidates for ZIKV are at different stages of development, none of them have received Food and Drug Authority approval for use up to now. The issue of side effects associated with these drugs in vulnerable newborns and pregnant women is a major obstacle in the therapeutic pathway.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Asian Pacific journal of tropical medicine PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-TROPICAL MEDICINE

CiteScore

4.00

自引率

9.70%

发文量

1936

审稿时长

3-8 weeks

期刊介绍： Asian Pacific Journal of Tropical Medicine (ISSN 1995-7645 CODEN: APJTB6), a publication of Editorial office of Hainan Medical University,is a peer-reviewed print + online Monthly journal. The journal''s full text is available online at http://www.apjtm.org/. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository. APJTM aims to provide an academic communicating platform for international physicians, medical scientists, allied health scientists and public health workers, especially those of the Asia-Pacific region and worldwide on tropical medicine, infectious diseases and public health, and to meet the growing challenges of understanding, preventing and controlling the dramatic global emergence and re-emergence of infectious diseases in the Asia-Pacific. The journal is proud to have an international and diverse editorial board that will assist and facilitate the publication of articles that reflect a global view on tropical medicine, infectious diseases and public health, as well as emphasizing our focus on supporting the needs of public health practitioners. The APJTM will allow us to seek opportunities to work with others who share our aim, and to enhance our work through partnership, and to uphold the standards of our profession and contribute to its advancement.